Randomized phase II study of 3 doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer

Cancer Science, 06/08/2012

TAS–108 at all dose levels was well tolerated and appeared to have no harmful effects in terms of the variables examined in this study. The authors conclude that the optimal dose of TAS–108 among the 3 doses is 40mg, once daily, for further studies.

Print Article Summary Cat 2 CME Report